Biome Australia Ltd
BIO
Company Profile
Business description
Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals vitamins and weight management products and live biotherapeutics. The company has one operating segment: researching, developing, manufacturing and distributing evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
Contact
192-194 Johnston Street
CollingwoodVIC3066
AUST: +61 390175800
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2026
Employees
30
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 66.60 | -0.72% |
| CAC 40 | 8,311.74 | 28.82 | -0.35% |
| DAX 40 | 24,914.88 | 62.19 | 0.25% |
| Dow JONES (US) | 49,507.81 | 613.59 | -1.22% |
| FTSE 100 | 10,446.35 | 43.91 | 0.42% |
| HKSE | 26,567.12 | 465.42 | -1.72% |
| NASDAQ | 22,571.09 | 495.37 | -2.15% |
| Nikkei 225 | 56,941.97 | 697.87 | -1.21% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,840.48 | 7.72 | 0.11% |
| S&P/ASX 200 | 8,917.60 | 55.30 | -0.62% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |